Reovirus is a double-stranded RNA virus with demonstrated oncolysis or preferential
replication in cancer cells. The oncolytic properties of reovirus appear to be dependent, in …

In the search for novel strategies, oncolytic virotherapy has recently emerged as a viable
approach to specifically kill tumor cells. Unlike conventional gene therapy, it uses replication …

Purpose: Early clinical trials are under way exploring the direct oncolytic potential of
reovirus. This study addresses whether tumor infection by reovirus is also able to generate …

Reovirus is a benign human virus that was recently found to have oncolytic properties and is
currently in clinical trials as a potential cancer therapy. We have previously demonstrated …

Oncolytic viruses can exert their antitumor activity via direct oncolysis or activation of
antitumor immunity. Although reovirus is currently under clinical investigation for the …

To investigate tumor‐selective viral replication, we compared several tumorigenic human
cell lines to nontumorigenic human cells from the blood for the sensitivity to become infected …

Background Reolysin® is reovirus serotype 3-Dearing strain, a double-stranded replication-
competent RNA non-enveloped icosahedral virus. It induces cytopathic and anti-cancer …

Tumor-associated immunosuppressive strategies, such as lack of tumor antigen recognition
and failure of lymphocyte activation and homing, resist the development of tumor-specific …

Purpose This open-labeled, phase I clinical trial was designed to determine the safety and
tolerability of percutaneous intralesional administration of wild-type oncolytic revovirus type …

Squamous cell carcinomas are the most common head and neck malignancies. Significant
progress has been made in standard therapeutic methods combining surgery, radiation, and …